Gastric Clinical Trials in Boston, Massachusetts

43 recruitingBoston, Massachusetts

Showing 120 of 43 trials

Recruiting
Phase 1Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerColorectal, CancerGastric Cancer+10 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Colorectal, CancerEsophageal CancerGastric Cancer+6 more
Sutro Biopharma, Inc.200 enrolled6 locationsNCT07227168
Recruiting
Not Applicable

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Gastric CancerIn Situ Breast CancerInvasive Breast Cancer+3 more
Brigham and Women's Hospital70 enrolled2 locationsNCT04368702
Recruiting
Phase 2

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Phase 1Phase 2

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Colorectal, CancerEsophageal CancerPancreatic Cancer+1 more
Lumicell, Inc.66 enrolled1 locationNCT02584244
Recruiting
Phase 1

IKS014 in Advanced Solid Tumors That Express HER2

Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.165 enrolled12 locationsNCT05872295
Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Phase 1

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

HER2-low Breast CancerHER2-positive Breast CancerHER2-positive Colorectal Cancer+3 more
Mersana Therapeutics162 enrolled14 locationsNCT05514717
Recruiting
Phase 2

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Breast CancerEsophageal CancerPancreatic Cancer+13 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194
Recruiting
Not Applicable

Comprehensive Outcomes for After Cancer Health

Breast CancerMetastatic Breast CancerGastric Cancer+8 more
Pack Health625 enrolled7 locationsNCT05349227